ES2421605T3 - Inhibidores de trastorno isquémico o enfermedades - Google Patents

Inhibidores de trastorno isquémico o enfermedades

Info

Publication number
ES2421605T3
ES2421605T3 ES08724144T ES08724144T ES2421605T3 ES 2421605 T3 ES2421605 T3 ES 2421605T3 ES 08724144 T ES08724144 T ES 08724144T ES 08724144 T ES08724144 T ES 08724144T ES 2421605 T3 ES2421605 T3 ES 2421605T3
Authority
ES
Spain
Prior art keywords
diseases
ischemic disorder
inhibitors
disorder inhibitors
ischemic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08724144T
Other languages
English (en)
Inventor
Lars Edvinsson
Saema Ansar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pronas Pharma AB
Original Assignee
Pronas Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pronas Pharma AB filed Critical Pronas Pharma AB
Application granted granted Critical
Publication of ES2421605T3 publication Critical patent/ES2421605T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

El uso de al menos un inhibidor seleccionado a partir del grupo constituido por U0126, SB590885 y SB386023b para la producción de un medicamento para el tratamiento del daño isquémico, donde el medicamento se administra entre >1 y 6 horas tras el inicio del daño isquémico.
ES08724144T 2007-03-30 2008-03-25 Inhibidores de trastorno isquémico o enfermedades Active ES2421605T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0700814 2007-03-30
PCT/SE2008/000218 WO2008121044A1 (en) 2007-03-30 2008-03-25 Ischemic disorder or disease inhibitors

Publications (1)

Publication Number Publication Date
ES2421605T3 true ES2421605T3 (es) 2013-09-04

Family

ID=39808527

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08724144T Active ES2421605T3 (es) 2007-03-30 2008-03-25 Inhibidores de trastorno isquémico o enfermedades

Country Status (5)

Country Link
US (1) US8273771B2 (es)
EP (1) EP2139512B1 (es)
ES (1) ES2421605T3 (es)
PL (1) PL2139512T3 (es)
WO (1) WO2008121044A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2139512B1 (en) * 2007-03-30 2013-04-24 Pronas Pharma AB Ischemic disorder or disease inhibitors
AU2011264833B2 (en) * 2010-06-09 2014-07-03 Dana-Farber Cancer Institute, Inc. A MEK 1 mutation conferring resistance to RAF and MEK inhibitors
US20190076510A1 (en) * 2017-09-13 2019-03-14 The Regents Of The University Of Michigan Protein kinase c inhibition to extend tissue plasminogen activator treatment for ischemic disease
CN107976481B (zh) * 2017-11-01 2020-04-07 广西壮族自治区食品药品检验所 一种中药材中钪含量的检测方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319955B1 (en) 1998-01-06 2001-11-20 The General Hospital Corporation Use of MEK1 inhibitors as protective agents against damage due to ischemia
WO2006130090A1 (en) 2005-06-03 2006-12-07 Pronas Pharma Ab Use of a substance which inhibits endothelin type b and 5-hydroxytryptamine type 1b receptor upregulation in the treatment of ischemic disorders
EP2139512B1 (en) * 2007-03-30 2013-04-24 Pronas Pharma AB Ischemic disorder or disease inhibitors

Also Published As

Publication number Publication date
WO2008121044A1 (en) 2008-10-09
PL2139512T3 (pl) 2013-09-30
US20100152248A1 (en) 2010-06-17
US8273771B2 (en) 2012-09-25
EP2139512A1 (en) 2010-01-06
EP2139512B1 (en) 2013-04-24
EP2139512A4 (en) 2010-06-02

Similar Documents

Publication Publication Date Title
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
CL2008001024A1 (es) Compuestos derivados de ftalazinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades cardiovasculares, parkinson, enfermedades inflamatorias, esclerosis multiple, cancer, entre otras
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
CR20120177A (es) Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes
CR20110224A (es) Pirazolopirimidina inhibidor jak compuestos y metodos
DOP2006000170A (es) Nuevos derivados de espirocromanona
AR079208A2 (es) Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica
CR20120296A (es) Nuevos compuestos de espiropiperidina
ECSP088358A (es) Tratamiento y profilaxis de microangiopatías
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
ECSP055745A (es) Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
BRPI0412999A (pt) 2-aminotetralina substituìda para tratamento de depressão
ES2531516T3 (es) Uso de escina
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
CL2015002346A1 (es) Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
CY1110658T1 (el) Χρηση του καρραγηνου για τη θεραπεια μολυνσεων απο ρινοϊο
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
AR079945A1 (es) Derivados de pirazina como inhibidores de glucogeno sintasa quinasa 3 (gsk3)
CL2009000964A1 (es) Compuestos derivados de 1-aril-2-imino-1,2-dihidropiridina-3-carboxamida, antagonista del receptor adrenergico alfa 1d, composicion farmaceutica que los comprende; y su uso para el tratamiento o profilaxis de enfermedades del tracto urinario inferior.
ECSP10010145A (es) Uso de 3,11b-cis-dihidrotetrabenazina en el tratamiento de la esclerosis múltiple y la mielitis autoinmunitaria
UY28255A1 (es) Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del veger
EA201401231A1 (ru) Фармацевтические комбинации, предназначенные для лечения метаболических нарушений
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.